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Meta-analysisAlmond is rich in antioxidants and phytochemicals such as methylquercetin, protocatechuic acid, cate-
chin, flavonoids, p-hydroxybenzoic acid, resveratrol, vanillic acid, and kaempferol. The aim of the present
study was to systematically review and dose-response meta-analyses the effects of almond consumption
on systolic and diastolic blood pressure (SBP/DBP), respectively, in Randomized Controlled Trials (RCTs).
A systematic search was performed in PubMed/MEDLINE, web of sciences and SCOPUS by 2 researchers,
independently to identify randomised controlled trials up to July 2019. There were no time or language
restrictions. PRISMA guidelines were followed in conducting this meta-analysis. Fifteen studies with 21
arms, containing 853 participants, reported SBP as an outcome measure. Pooled results showed signifi-
cant reduction in SBP (WMD: 0.90 mmHg, 95% CI: 1.74, 0.06, Pheterogeneity = 0.94) by almond inter-
vention. There is no significant effect from almond consumption on DBP (WMD: 0.67 mmHg, 95% CI:
1.93, 0.60, Pheterogeneity = 0.001). Meta-regression analysis showed dose of used almond (g/d) as source
of heterogeneity between results of DBP. In conclusion results of this meta-analysis showed reduce effect
of Almonds on systolic blood pressure.
 2020 The Author(s). Published by Elsevier B.V. on behalf of King Saud University. This is an open access
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Hypertension is one of the important causes of mortality in
worldwide (Mills et al., 2016). Its prevalence is increasing dramat-
ically; there was a 10.5% increase of the death rate attributed to
high blood pressure in the US from 2005 to 2015 (Benjamin
et al., 2018). Worldwide, 1.3 billion hypertensive people have been
diagnosed in 2010. According to WHO, the number 1 cause of
death in 2016 is the ischemic heart disease and the stroke, a main
complication of this silent killer. Eleven percent of children and
young adolescents in the US were prone to this non-
communicable disease in 2012 according to the American Heart
Association (Mills et al., 2016).
Nutrition, in conjunction with pharmacotherapy, plays an
important role in either increasing or managing the high blood
pressure; high sodium chloride intake increases the incidence
and alcohol consumption may cause an acute elevation in blood
pressure. In contrast, high intake of potassium, polyunsaturated
fatty acids, and protein may help in lowering blood pressure
(Savica et al., 2010).
Almonds, a type of tree nut, are rich in vitamins, minerals,
mono-saturated and polyunsaturated fatty acid (Jaceldo-Siegl
et al., 2004). Recently, almonds have been advocated as a promis-
ing part of a healthy diet improving the blood pressure, weight,
and the lipid profile (O’Neil et al., 2016). Many studies reported
almond’s role in reducing serum levels of triglycerides, low-
density lipoprotein, and total cholesterol (Griel and Kris-
Etherton, 2006; Sabaté et al., 2010). In addition, almonds affect
the appetite and the post-ingestive metabolism positively without
increasing the body mass index (Tan and Mattes, 2013).
While some studies have shown almond to have a potential
reducing effect on SBP and DBP (Choudhury et al., 2014; Dhillon
et al., 2016), other studies have not shown significant effects
(Chen et al., 2015; de Souza et al., 2018; Foster et al., 2012; Liu
et al., 2018). The aim of present dose-response meta-analysis
was to determine the effect of almonds consumption on blood
pressure in adults.2. Methods
2.1. Literature search
For conducting the present systematic review and dose-
response meta-analysis, the Preferred Reporting Items of System-
atic Reviews and Meta-Analysis (PRISMA) statement guideline
was followed (23). Two authors (MB and CC) independently con-
ducted a search of the databases MEDLINE/PubMed, Web of
sciences, and Scopus up to July 2019. Medical subject headings
(MeSH) and non-MeSH (title and/or abstract) terms were used
for searching (Supplemental Table 1) and reference lists of
included studies were searched manually, too. No date or language
or grey literature restrictions were applied. Any disagreementsbetween authors were resolved by way of cooperative triangula-
tion with the senior author. Data from articles were extracted by
two authors, independently.
2.2. Study selection
Studies screened based on title and abstract in first step of
screening. In second step, we evaluate studies based on our inclu-
sion criteria in full text of them. Studies that met inclusion criteria
included in analysis.
2.3. Eligibility criteria
Studies were included if they involved: a) Parallel or cross over
randomized clinical trial (RCT) designs, b) consumption of Almond
as intervention c) reported blood pressure as outcome measure. d)
adults Animal, in-vitro, studies without control group, and review
papers were excluded. PICOS for this study was: P – public popula-
tion, I – intervention with Almond, C – placebo group, O – blood
pressure, and S – RCTs.
2.4. Statistical analyses
Effect sizes and 95% confidence intervals were reported for each
study.SD change of the mean difference was calculated using the
SD2 = [(SD baseline2 + SD final2)  (2  r  SD baseline  SD final)]
formula (Higgins and Green, 2011) if the studies did not report, it.
Included studies results combined by random effect model. Meta-
regression analysis based on used dose of almond conducted to
find source of heterogeneity. Heterogeneity among the studies
was assessment using the I-squared (I2) statistics. Funnel plots,
Begg’s and Egger’s weighted regression tests were used to assess-
ment publication bias (2); the trim and fill approach was used to
adjust for publication bias (Duval and Tweedie, 2000). Sensitivity
analysis was additionally conducted to investigate the individual
effect of each study on the overall analysis. Cochrane collabora-
tion’s Risk of Bias tool was used to assess included studies (4).
STATA software version 12 (STATA Corp, College119 station, Texas)
was used in all analyses.
3. Results
In our initial comprehensive systematic search from PubMed,
Scopus, and web of sciences, 104 papers were located. Fig. 1
depicts a flow diagram of the search strategy. After removing
duplicates, 66 articles were identified for title and/or abstract
screening. Screening led to the removal of 39 articles Subsequently,
11 additional articles were removed because they did not meet the
inclusion criteria during afull text screening. Finally, 15 articles
with 21 arms were included for meta-analysis (Abazarfard et al.,
2014; Chen et al., 2015, 2017; Choudhury et al., 2014; de Souza
et al., 2018; Dhillon et al., 2016, 2018; Foster et al., 2012;
Fig. 1. Flow chart of included studies.
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et al., 2018; Richmond et al., 2013; Sweazea et al., 2014; Tan and
Mattes, 2013; Wien et al., 2010).3.1. Study characteristics
Characteristics of the eligible studies are detailed in Table 1.
Studies were published from 2002 to 2018. Sample sizes ranged
from 6 to 137. Seven studies were conducted in the USA (Chen
et al., 2015; Dhillon et al., 2016, 2018; Foster et al., 2012;
Johnston et al., 2017; Sweazea et al., 2014; Wien et al., 2010), 1
in New Zealand (Richmond et al., 2013), 1 in Canada (Jenkins
et al., 2002), 1 in Taipei (Chen et al., 2017), Brazil (de Souza
et al., 2018), UK (Choudhury et al., 2014), Korea (Liu et al., 2018),
Pakistan (Jamshed et al., 2015), and Australia (Tan and Mattes,
2013). Length of follow up ranged from 3 to 78 weeks. The quality
of eligible studies was evaluated using the Cochrane collabora-
tion’s Risk of Bias tool for quality assessment of RCT’s, where the
majority studies were assigned low risk (Fig. 2).3.2. Meta-analysis results
Sixteen studies, with 21 arms, containing 853 participants,
reported SBP as an outcome measure. Pooled results did not show
any significant reductive effect from almonds on SBP (WMD:
0.90 mmHg, 95% CI: 1.74, 0.06, I2 = 00%, Pheterogeneity = 0.94)
(Fig. 3).
Almond consumption did not show any significant effect on
DBP (WMD: 0.67 mmHg, 95% CI: 1.93, 0.60, I2 = 52%, Pheterogeneity
= 0.001). Meta-regression analysis based on used dose of almond
was performed and showed dose of almond as a source of hetero-
geneity (I2 = 0%). There was inverse relation between dose of
almond and blood pressure (Coef = 0.0097) but this relation
was not statistically significant (p = 0.72) (Supplemental Fig. 1).3.3. Publication bias and sensitivity analysis
There is not any asymmetry in the funnel plot of included studies
for SBP (Fig. 4), but therewas an asymmetry between included stud-
ies for DBP. The Egger’s and Begg’s tests for SBP were p = 0.63 and
p = 0.80, respectively, and p = 0.01 and p = 0.09 for DBP, respectively.
A Trim and fill method was used to adjust for publication bias for
DBP; results showed 32 papers and a significant reduction in DBP
(WMD:2.91mmHg, 95%CI:4.11,1.71). The sensitivity analysis
showed no significant differences beyond the 95% CI of calculated
combined results for each of included studies (Supplemental Fig. 2).4. Discussion
Whilst consumption of almonds has been shown to elicit
improvements in triglycerides, total cholesterol (Sabaté et al.,
2010), low density lipoprotein-cholesterol, and various cardiovas-
cular disease risk factors (Griel and Kris-Etherton, 2006; Li et al.,
2010); its’ widescale recommendation and uptake remains incon-
sistent. Observational studies have reported that almond con-
sumption is associated with a reduced risk of developing various
non-communicable diseases, including; elevated blood pressure
(hypertension), coronary artery disease, and type 2 diabetes
(Jiang et al., 2002; Kris-Etherton et al., 2001). However, despite
numerous reports suggesting almond consumption may elicit pos-
itive effects on vascular health, there still exists some equivocality,
particularly when considered concurrently with weight-loss and
blood lipid markers (Foster et al., 2012). Moreover, to date, no sys-
tematic compilation of relevant data has taken place; thus, we
sought to conduct a systematic review and dose-response meta-
analysis of the effect of almond consumption on blood pressure.
In accord with the aim of this study, we found that, overall, almond
consumption had significant reduction in SBP but on DBP. How-
ever, following meta-regression analyses, we found that a reduc-
tion in DBP by higher dose of Almond.
Lifestyle modifications consisting of regular adherence to phys-
ical activity guidelines, reduced consumption of fat, increased con-
sumption of plant-based foods and smoking cessation are
recommended to complement pharmacological regimens in the
management and prevention of hypertension, and related comor-
bidities (Booth et al., 2014). However, a recent meta-analysis
investigating dietary-based almond interventions asserted that
the current evidence base does not support almond consumption
specifically for lipid altering effects (Phung et al., 2009), whilst
dietary intervention with almonds demonstrably improves
biomarkers of insulin sensitivity in prediabetic adults (Wien
et al., 2010). Almond consumption has been shown to positively
impact markers of inflammation and hemostasis, respectively,
independent of dose (Rajaram et al., 2010). Furthermore, almonds
represent major dietary sources of a-tocopherol and mono-
unsaturated fatty acids and regular consumption evidently dimin-
ishes the risk of early mortality attributed to coronary heart dis-
ease, myocardial infarction (Hu et al., 1997), and sudden cardiac
death (Albert et al., 2002). Moreover, nutrients constituent within
almonds are associated with beneficial cardiovascular outcomes,
such as antioxidant flavonoids and L-arginine, which is key for
the synthesis of the vasodilatory molecule, nitric oxide. The precise
nutrient composition of almonds differs dependent on the cultivar
(Barreira et al., 2008), and the overall positive effects of almonds
may conceivably be attributable to the milieu of nutrients.
Some studies, such as Dhillon et al., have reported that almond
consumption results in greater proportional reductions of trunk
and total body fat as well as DBP, and thus may help to lower meta-
bolic disease risk in obesity (Dhillon et al., 2016); however, in such
examples, participants were concurrently following an energy
restriction protocol and were overweight or obese at study com-
mencement. Thus, whilst consuming almonds, alongside calorie-
restriction, was more beneficial than calorie restriction alone.
Epidemiological and clinical evidence demonstrates that adher-
ence to a diet enriched in mono-unsaturated fatty acids and toco-
pherols from nuts, can reduce blood pressure (SBP and DBP) and
blood lipid levels (Einarsson et al., 1985). Indeed, regular nut con-
sumption, demarcated by 1–4 times per week, has been reported
to diminish the risk of early mortality attributed to cardiovascular
disease by, roughly, one-quarter (Dreher et al., 1996). Indeed,
mechanistically, muscle relaxation is putatively mediated by the
availability of nitric oxide (Hijmering et al., 2002). Almonds are
Table 1
Characteristics of included studies.
First Author Country Year Study
Population
(n)
Age Sex (1.
male 2.
female
3. both)
Dose of Almond basic participant
disease
type of Almond Duration of treatment
(week)
Chen USA 2015 45 61.8 3 85 g/d CAD patients Raw whole almonds 2  6 wk intervention
phases
Chen USA-
collected
in Taipe
2017 33 54.9 3 60 g/d T2DM Roasted almonds 12 wk  2 phases (CO)
Choudhury UK 2014 60 Middle age 56y; young male
22.1y; young male with risk
factors 27.3y; CL gp
allocated from the above 3
groups
1 50 g/d healthy middle-aged
(MA); Healthy yound
(HY); ‘‘young, at risk
(YR); Habitual
(control)
not specified-2 bags 4wk
Dhillon USA 2016 50 18–60 3 providing 15% of Energy Overweight and
obese individuals
Dry roasted, lightly salted 12 wks
Foster USA 2012 123 46.8 3 two 28-g packages of almonds
(24) Over the first 5 wk of
treatment, participants received
whole, raw almonds only.
At week 6, roasted almonds were
introduced and, over time, a
variety of isocaloric, flavored
almonds were used.
Overweight and
obese individuals
first 5 wk – whole, raw almonds only.At
week 6, roasted almonds were
introduced over time:over time,a variety
of isocaloric, flavored almonds were
used.
18 months
Jaapna
Dhillon
USA 2018 73 18 3 56.7 g/day – dry roasted almonds 12 wks
Jamshed Pakistan 2015 113 32–86 3 10 g/d PA: Pakinstan almonds AA:
american almonds
Included CAD
patients with optimal
LDL cholesterol and
low HDL cholesterol
Pakistan almonds (Talwar (sword shape)
& American almonds (Carmel variety,
California Shelled. Soak overnight and
eat after removing the skin, before
breakfast
12 wk
Jenkins Canada 2002 27 64 3 73.3 g/d hyperlipidemic
subjects
whole raw unblanched almonds 3 phases 1 month each
Johnston USA 2017 12 45–60 3 2.5 oz/d sedentary older
adults
raw, whole 8 wks (wk 1–5 walking)
but group comparisons
with almonds vs cookie
butter were on wk 6–8
Lui Rep
Korea
2018 85 26 3 56 g/d Healthy adults whole 20wks
Richmond New
Zealand
2018 22 62 2 30 g/d postmenopausal
women with type 2
diabetes
whole nature almonds 3wk x2 (CO)
Souza Brazil 2018 46 20–59 2 20 g Adult women ,
overweight or obese
roasted Baru almonds 8 wks
Sweazea USA 2014 21 55 3 1.5 oz/5–7 days a wk Health adults with
T2D
skins 12 wk
Tan Australia 2013 137 31 3 43 g/d in 4 conditions Risk of T2D Dry roasted, lightly salted 4 wks 5 groups
Wien, USA 2010 6 53 3 Participants consumed an ADA
diet with 20% from almonds and
avoided other tree nuts and
peanuts (intervention) energy
from almonds
Prediabetes no mentioned 16 wks
1760
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Fig. 2. Cochrane risk of bias assessment.
Fig. 3. Meta-analysis of effect of Almond consumption on:
Fig. 4. Funnel plot to assess publication bias.
Z. Li et al. / Journal of King Saud University – Science 32 (2020) 1757–1763 1761abundant in L-arginine, which is a rate-limiting substrate for the
production of endothelial nitric oxide and in the synthesis of vita-
min E, and acts as a scavenger of free radicals; in combination, this
is asserted to increase bioavailable nitric oxide. Age-dependent
vascular stiffness might also be a mitigating factor, where,
although the mechanism by which baroreceptor control is medi-
ated via nutrients is not well defined, some empirical evidence
suggests that redox imbalances might precipitate high blood pres-
sure and baroreflex responses, whilst tocopherol can modulatevascular responses (El-Mas et al., 2012; Wu et al., 2011). Further-
more, lipid dysfunction may intermediate this effect, where hyper-
lipidemia in hypertensive and obese patients has been attributed
to baroreceptor reflex impairment, resulting in hypertension (SBP
and DBP) (Gadegbeku et al., 2002).5. Strengths and limitations
The primary strength of the present study was that we assessed
the impact of almond consumption on blood pressure, which has
not previously been reported; and given the potential influence
on clinical and holistic practice, this represents an important addi-
tion to the literature. The evidence base, prior to this investigation,
1762 Z. Li et al. / Journal of King Saud University – Science 32 (2020) 1757–1763was far from consensual, and thus necessitated a meta-analytical
evaluation, which we have provided. An additional strength of
the current meta-analysis is the heterogeneous sample assimi-
lated, with a range of demographics, ethnicities, and ages. More-
over, we were also able to stratify our analyses based upon
dosage of supplementation. However, there are some limitations
that need to be appreciated within this meta-analysis. Varying
diets, ad libitum or prescribed, may elicit different magnitudes of
weight change during trials, possibly confounding the results of
the meta-analysis; moreover, it should be considered that control
group diets designed to mimic the overall energy content of
almonds may also represent a confounding variable. Bias associ-
ated with attrition may be a concern in the present meta-
analysis, however, the compliance of participants to study diets
was scarcely reported; consequently, we were unable to assess
attrition bias in the included studies and their consequential
impact on the overall results of the meta-analysis.
6. Conclusion
The current body of evidence supports the ingestion of almonds
for their beneficial effect on blood pressure. However, both the vas-
cular moderating effects and the safety and acceptability of almond
consumption should be further investigated in large, randomized,
double-blind, placebo-controlled trials of longer duration, across
age groups.
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